Pharmacokinetic and Pharmacodynamic Considerations for the Use of Monoclonal Antibodies in the Treatment of Bacterial Infections

@inproceedings{WangLin2018PharmacokineticAP,
  title={Pharmacokinetic and Pharmacodynamic Considerations for the Use of Monoclonal Antibodies in the Treatment of Bacterial Infections},
  author={Shun Xin Wang-Lin and Joseph P Balthasar},
  year={2018}
}
Antibiotic-resistant bacterial pathogens are increasingly implicated in hospitaland community-acquired infections. Recent advances in monoclonal antibody (mAb) production and engineering have led to renewed interest in the development of antibody-based therapies for treatment of drug-resistant bacterial infections. Currently, there are three antibacterial mAb products approved by the Food and Drug Administration (FDA) and at least nine mAbs are in clinical trials. Antibacterial mAbs are… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-2 of 2 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 129 references

The antibiotic resistance crisis: part 1: causes and threats.

P & T : a peer-reviewed journal for formulary management • 2015
View 3 Excerpts
Highly Influenced

How the Immune System Works, 4th ed.; Wiley-Blackwell

L. Sompayrac
2012
View 4 Excerpts
Highly Influenced

Pharmacokinetics of a monoclonal anti-acinetobacter baumannii k2 capsule antibody in mice

S. X. Wang-Lin, T. A. Russo, J. P. Balthasar
Unpublished work • 2018
View 2 Excerpts

Antibodies to Mycobacterium tuberculosis.

The New England journal of medicine • 2017
View 1 Excerpt

Antibody dependent enhancement of acinetobacter baumannii infection through immunoglobulin g engagement of fc gamma receptors

S. X. Wang-Lin, R. Olson, +3 authors J. P. Balthasar
J. Immunol • 2017
View 1 Excerpt

Similar Papers

Loading similar papers…